← Eichor
Condition: Large B Cell Lymphoma Lbcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Large B Cell Lymphoma Lbcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Phase 2 · 1 location(s) · Shanghai Ming Ju Biotechnology Co., Ltd. · NCT06479356CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Phase 2 · 1 location(s) · Zhejiang University · NCT04661020Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Phase N/A · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07524816Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therap
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05464719Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2 · 77 location(s) · Allogene Therapeutics · NCT06500273The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refra
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07240194A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R
Phase 1/Phase 2 · 31 location(s) · AstraZeneca · NCT06542250CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07538635AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Phase 3 · 68 location(s) · AstraZeneca · NCT07215585The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07514169Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06489808Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2 · 94 location(s) · AstraZeneca · NCT06526793Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relap
Phase 2 · 1 location(s) · Australasian Leukaemia and Lymphoma Group · NCT06287398ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07098364Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treat
Phase 2 · 1 location(s) · University of California, Davis · NCT06905509Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymph
Phase N/A · 73 location(s) · AbbVie · NCT06830759Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06104592Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With
Phase 1 · 1 location(s) · Tel-Aviv Sourasky Medical Center · NCT07361224
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.